Arvinas (ARVN) Stock Price, News & Analysis

Company Overview

Arvinas, Inc. (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers. ARV-110 (bavdegalutamide) is being evaluated for the treatment of metastatic castration-resistant prostate cancer, while ARV-471 (voredabolu) is in development for ER+/HER2- breast cancer. Both programs have shown favorable pharmacokinetic profiles in early-phase trials and reflect Arvinas’s strategy of advancing a focused pipeline of next-generation small molecules designed to degrade pathogenic proteins.

Since its founding in 2013 and incorporation in New Haven, Connecticut, Arvinas has established collaborative partnerships with leading pharmaceutical companies to expand the reach of its PROTAC platform. Agreements with Pfizer and Roche, among others, provide access to complementary expertise in oncology and other therapeutic areas. The company conducts research and development in the United States and maintains relationships with regulatory authorities in North America and Europe as it pursues global clinical development.

Arvinas is led by President and Chief Executive Officer Robert A. Ross, who joined the company in 2022 following a tenure at a major pharmaceutical association. Under his leadership, the company continues to advance its pipeline while building a broader platform for targeted protein degradation. Arvinas remains committed to translating its scientific innovations into transformative therapies for patients with unmet medical needs.

Key Stats

• Today's Range: $7.01 to $7.37
• 50-Day Range: $7.15 to $11.37
• 52-Week Range: $6.05 to $14.51
• Volume: 981,344 shs
• Average Volume: 836,803 shs
• Market Capitalization: $465.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.42
• Consensus Rating: Hold

Arvinas Stock Analysis - MarketRank™

Arvinas scored higher than 63% of companies evaluated by MarketBeat, and ranked 299th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Arvinas has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on no strong buy ratings, 8 buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

Arvinas has a consensus price target of $15.42, representing about 113.8% upside from its current price of $7.21.

Amount of Analyst Coverage

Arvinas has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arvinas are expected to decrease in the coming year, from ($2.83) to ($3.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arvinas is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arvinas is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arvinas has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.87% of the float of Arvinas has been sold short.

Short Interest Ratio / Days to Cover

Arvinas has a short interest ratio ("days to cover") of 5.88.

Change versus previous month

Short interest in Arvinas has recently decreased by 6.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arvinas does not currently pay a dividend.

Dividend Growth

Arvinas does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.41

News Sentiment

Arvinas has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Arvinas this week, compared to 5 articles on an average week.

Search Interest

Only 6 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $427,598.00 in company stock.

Percentage Held by Insiders

7.30% of the stock of Arvinas is held by insiders.

Percentage Held by Institutions

95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/11/2026
• Today: 6/09/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARVN
• CIK: 1655759
• Web: www.arvinas.com
• Phone: (203) 535-1456
• Fax: N/A
• Employees: 420
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Arvinas: $15.42
• High Price Target: $24.00
• Low Price Target: $6.00
• Potential Upside/Downside: +113.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.46
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$80.80 million
• Net Margins: -247.54%
• Pretax Margin: -247.32%
• Return on Equity: -44.38%
• Return on Assets: -28.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.44
• Quick Ratio: 5.44

Sales & Book Value

• Annual Sales: $262.60 million
• Price / Sales: 1.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.76 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 64,520,000
• Free Float: 59,811,000
• Market Cap: $465.19 million
• Optionable: Optionable
• Beta: 1.74